# GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer

> **NCT07017829** · PHASE2 · RECRUITING · sponsor: **Roswell Park Cancer Institute** · enrollment: 28 (estimated)

## Conditions studied

- Advanced Lung Non-Small Cell Carcinoma
- Metastatic Lung Non-Small Cell Carcinoma
- Stage III Lung Cancer AJCC v8
- Stage IV Lung Cancer AJCC v8

## Interventions

- **BIOLOGICAL:** Anti-CFH Monoclonal Antibody GT103
- **PROCEDURE:** Biopsy Procedure
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Echocardiography Test
- **PROCEDURE:** Magnetic Resonance Imaging
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT07017829
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2028-12-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07017829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07017829, "GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07017829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*